The treatment, lecanemab, has already been approved in some other countries, including the U.S., the U.K., Japan, Mexico and ...

The device, developed in the U.S. by the Michigan-based Renew Bioscience medical technology company, focuses on restoring ...

A new drug to treat Alzheimer’s Disease has been approved by Health Canada and it is the first drug that targets an ...

In recognition of Alzheimer’s Awareness Month, the Centers for Medicare and Medicaid Services should review and revise policies for Alzheimer’s disease therapies to clear the path for early ...

The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...

Lecanemab is the first medication approved in Canada that targets the buildup of amyloid plaque in the brain, which is ...

Richard Oakley of the Alzheimer's Society spoke to Newsweek about why now is an "exciting time" in the battle against the ...

The new treatment approach targets restoring normal blood vessel function instead of focusing on neurons or other brain cells, which has been the common strategy until now. A team of scientists co-led ...

A new study is reviving hope that a twice-daily pill can slow down Alzheimer's in people whose genes put them at high risk ...

Alzheimer's disease is a progressive neurological disorder characterised by memory loss and cognitive decline, caused by ...

Alzheimer’s Research UK said the new study “adds to the growing evidence that repairing the blood-brain barrier (BBB) itself could offer a new way to treat Alzheimer’s,” but added that it is too early ...

More than 70% of people over 70 years old will one day develop cardiovascular disease, highlighting the need for effective ...